中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
12期
1827-1828
,共2页
糖尿病肾病%辛伐他汀%阿魏酸钠
糖尿病腎病%辛伐他汀%阿魏痠鈉
당뇨병신병%신벌타정%아위산납
Diabetic nephropathy%Simvastatin%Ferulate
目的 探讨辛伐他汀联合阿魏酸钠治疗早期糖尿病肾病(DN)的临床疗效.方法 将106例DN患者采用数字表法随机分为两组,每组各53例,在均采取常规治疗基础上,对照组给予辛伐他汀,观察组采取辛伐他汀联合阿魏酸钠治疗,比较两组临床治疗效果.结果 观察组总有效率为92.45％,显著高于对照组的73.58％(x2=8.992,P＜0.05);观察组24h尿微量白蛋白(Upro)、Cr、BUN及CRP水平分别为(50.72 ±7.74) mg/24 h、(70.01±8.56) μmol/L、(3.87±0.54) mmol/L和(3.51±0.63) mmol/L,均显著低于对照组的(83.74±7.92) mg/24 h、(84.33±9.01) μmol/L、(5.03±0.62) mmol/L和(5.52±0.61) mmol/L,差异均有统计学意义(t=7.73、6.59、8.62、9.30,均P＜0.05).结论 辛伐他汀联合阿魏酸钠治疗早期糖尿病肾病疗效显著,可有效改善患者临床症状,保护其肾功能,具有较好的临床应用价值.
目的 探討辛伐他汀聯閤阿魏痠鈉治療早期糖尿病腎病(DN)的臨床療效.方法 將106例DN患者採用數字錶法隨機分為兩組,每組各53例,在均採取常規治療基礎上,對照組給予辛伐他汀,觀察組採取辛伐他汀聯閤阿魏痠鈉治療,比較兩組臨床治療效果.結果 觀察組總有效率為92.45％,顯著高于對照組的73.58％(x2=8.992,P＜0.05);觀察組24h尿微量白蛋白(Upro)、Cr、BUN及CRP水平分彆為(50.72 ±7.74) mg/24 h、(70.01±8.56) μmol/L、(3.87±0.54) mmol/L和(3.51±0.63) mmol/L,均顯著低于對照組的(83.74±7.92) mg/24 h、(84.33±9.01) μmol/L、(5.03±0.62) mmol/L和(5.52±0.61) mmol/L,差異均有統計學意義(t=7.73、6.59、8.62、9.30,均P＜0.05).結論 辛伐他汀聯閤阿魏痠鈉治療早期糖尿病腎病療效顯著,可有效改善患者臨床癥狀,保護其腎功能,具有較好的臨床應用價值.
목적 탐토신벌타정연합아위산납치료조기당뇨병신병(DN)적림상료효.방법 장106례DN환자채용수자표법수궤분위량조,매조각53례,재균채취상규치료기출상,대조조급여신벌타정,관찰조채취신벌타정연합아위산납치료,비교량조림상치료효과.결과 관찰조총유효솔위92.45％,현저고우대조조적73.58％(x2=8.992,P＜0.05);관찰조24h뇨미량백단백(Upro)、Cr、BUN급CRP수평분별위(50.72 ±7.74) mg/24 h、(70.01±8.56) μmol/L、(3.87±0.54) mmol/L화(3.51±0.63) mmol/L,균현저저우대조조적(83.74±7.92) mg/24 h、(84.33±9.01) μmol/L、(5.03±0.62) mmol/L화(5.52±0.61) mmol/L,차이균유통계학의의(t=7.73、6.59、8.62、9.30,균P＜0.05).결론 신벌타정연합아위산납치료조기당뇨병신병료효현저,가유효개선환자림상증상,보호기신공능,구유교호적림상응용개치.
Objective To investigate the clinical efficacy of simvastatin combined with ferulate in treatment of early diabetic nephropathy (DN).Methods 106 patients with DN were randomly divided into two groups by random number table,and each group had 53 cases.The control group was given simvastatin,while the observation group was given simvastatin combined with ferulate,and the clinical outcomes were compared between the two groups.Results The total effective rate of the observation group was 92.45％,which was significantly higher than 73.58％ of the control group(x2 =8.992,P ＜ 0.05) ; after treatment,the Upro,SCr,BUN and CRP levels of the observation group were (50.72 ± 7.74) mg/24h,(70.01 ± 8.56) μmol/L,(3.87 ± 0.54) mmol/L and (3.51 ± 0.63) mmol/L,which were significantly lower than (83.74 ± 7.92) mg/24h,(84.33 ± 9.01) μmol/L,(5.03 ± 0.62) mmol/L and (5.52 ± 0.61) mmol/L of the control group,the difference was statistically significant (t =7.73,6.59,8.62,9.30,all P ＜ 0.05).Conclusion Simvastatin combined with ferulate in treatment of early diabetic nephropathy (DN) has significant effect,and it can effectively improve the clinical symptoms and protect renal function,and it has better clinical value.
